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I. INTRODUCTION 
An enzyme catalyzing the reversible transfer of an amino 
group between L-glutamic acid and pyruvic acid or other oxo 
acids was demonstrated by Braunstein and Kritzmann (1) in muscle 
and other animal tissues. Later, Gunsalus and co-workers (2) 
and Snell (3) established the role of pyridoxal 5'-phosphate 
(PLP) as the cofactor of aminotransferases. Since then an 
extensive literature has accumulated concerning various chemi­
cal, biological and medical aspects of PLP-dependent trans­
amination. Besides its role in transamination, PLP is an 
essential coenzyme for a variety of other enzymes that are in­
volved in all phases of nitrogen metabolism. The coenzyme acts 
as a reactive center in the active sites of the enzymes re­
quiring it. Besides the fundamental importance of PLP to 
enzymology, there are diseases involving PLP-dependent enzymes. 
For examples, vitamin Bg deficiency may be related to diabetes 
associated with abnormal tryptophan metabolism (4). Defective 
vitamin Bg-enzymes have been associated with the genetic 
diseases (5), xanthurenic aciduria, and cystathioninuria. It 
is clearly of importance to investigate how enzymes of this 
group function. 
This study deals with two aspects of certain analogues of 
the coenzyme pyridoxal phosphate: (1) Inhibitory properties 
that might be of pharmacological significance. (2) A possible 
biochemical function for the 5'-phosphate group. 
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Vitamin Bg is an essential nutrient for living organisms, 
and, as the coenzyme, is required by a variety of enzyme 
systems. This fact provides a good opportunity for rational 
design of inhibitors that might be used as drugs. Many 
pharmacological effects have been observed with analogues of 
vitamin Bg, such as inhibition of the growth of microorganisms 
(6, 7) and tumors (8, 9). The effects of these agents on the 
central nervous system (9, 10) and on sickle cell hemoglobin 
(11) have also been documented. Although numerous vitamin Bg 
analogues have been synthesized (12, 13), they have not yet 
been studied enough, either from a pharmacological point of 
view or in investigations of enzyme mechanisms. Although 
systematic synthetic schemes have been developed (12) , these 
analogues still remain difficult to make. Here the author will 
discuss a possible new scheme which can increase the yields and 
thus makes it easier to study vitamin Bg analogues. 
The coenzyme PLP not only acts as a reactive center of 
enzymes but it also provides us with a natural probe for the 
investigation of the functioning of enzymes. Therefore, a full 
understanding of the physical organic characteristics of the 
functional groups of this coenzyme should lead to a better 
understanding of PLP-dependent enzymes. It has been fully 
established that the 4-formyl, 3-hydroxyl, and pyridine nitro­
gen are essential for catalysis. However, the role of the 5'-
phosphate of the native coenzyme in the holoenzyme is still 
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obscure. Therefore the analogues modified in the 5'-chain 
were made in this laboratory in order to explore the role of 
the 5'-phosphate in the catalytic action of L-aspartate: 2-
oxoglutarate aminotransferase (EC 2.6.1.1.) 
The structures and abbreviations of these analogues are 
shown as follows. 
CHO 0 
II 
CH--0-P-0H 
^ I 
0 
H 
CHgNHg 0 
II 
CHg-O-P-OH 
0 
H 
pyridoxal 5'-phosphate pyridoxamine 5'-phosphate 
(PLP) (PMP) 
diethyl 5-14-formyl-3-
hydroxy2-methyl) pyridyl-
methyl phosphonate [(Et) 2 MP] 
5-(4-formyl-3-hydroxy-2-
methyl) pyridylmethyl 
phosphoric acid (MPA) 
4 
HO. 
H3C 
CHO 
o 
0 
II 
.CH--P-OH 
^ I 
CH2 
CHo 
CHO 
N 
CH^-S-OH 
ethyl 5-(4-formyl-3-hydroxy-
2-methyl) pyridylmethyl 
phosphonate (EtMP) 
5-deoxypyridoxal 5'-sulfonate 
(PLSN) 
CHO 
CHgCHgCOOH 
CHgNHg'HCl 
CHgCHgCOOH 
5 ' -carboxyinethyl-5-
deoxypyridoxal (CMDPL) 
5'-carboxymethyl-5-deoxy-
pyridoxamine dihydrochloride 
(CMDPM) 
CHO 
CH_-0-P-0H 
^ I 
0 
CH^ 
CH% 
CHO 
0 
II 
CH--0-P-0H 2 I 
O 
ethyl pyridoxal 5'-phosphate 
(EtPLP) 
methyl pyridoxal 5 *-phosphate 
(MePLP) 
5 
pyridoxal (PL) 5- (4-fonayl-3-hydroxy-2-methyl) 
pyridylethyl phosphonic acid 
(EPA) 
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II. LITERATURE REVIEW 
A. Aspartate Aminotransferase 
An impressive mass of information concerning the structure 
and function of pyridoxal phosphate-dependent enzymes, espe­
cially aspartate aminotransferase (AAT) has been obtained and 
reviewed by several authors (14-18, 13). 
The general pattern of the chemical events occurring at 
the active sites has been established; the transamination 
proceeds through a number of discrete steps catalyzed by 
various well-disposed functional groups on the enzyme; conforma­
tional changes may contribute to placing the functional groups 
in the most appropriate position during the catalysis. However, 
the identity of some groups involved in catalysis is still 
ambiguous. The three-dimensional structure of the active site 
is not known although the amino acid sequence has been deter­
mined by two groups (19, 20). Well-ordered crystals of cyto­
plasmic aspartate aminotransferase have been first grown by 
vapor diffusion from solutions of polyethylene glycol in the 
laboratories of Arnone and Metzler (21a). The diffraction pat-
O 
tern extends beyond 2.8 A, indicating that this crystal form is 
suitable for high resolution X-ray analysis. Three dimensional 
intensity data for native and heavy-atom derivative crystals 
are currently being collected. Recently, a cytoplasmic AAT 
O 
from chicken heart was also crystallized and a 5 A resolution 
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map was obtained (21b). Perhaps an accurate knowledge of the 
enzyme's spatial atomic topography will provide a reliable 
basis for elaboration of the correct reaction mechanism. In 
this respect, AAT could offer great opportunities because, a 
series of substrate analogs are available, each of which forms 
predominantly a few of the intermediates of the overall process. 
AAT is particularly active in heart muscle, and in most 
procedures for purification of the enzyme, pig hearts are used 
as a readily available source. A highly purified cytoplasmic 
AAT was first obtained from pig heart by Jenkins et al. (22). 
AAT prepared by the usual method (22-24) contains only the 
anionic cytoplasmic isoenzyme. The mitochondrial isoenzyme, 
which is cationic, is largely destroyed by the heat treatment. 
Other methods (25-28) lead to the isolation of extensively puri­
fied and crystallized mitochondrial AAT. Martinez-Carrion et al. 
(27) has isolated no less than three main subforms from the 
cytosol AAT, a, g and y in the order of increasing anode 
mobility and decreasing catalytic activity. Marino et al. 
(29) was able to obtain five fractions by ampholine electro-
focusing. All subforms possess the same amino acid composition. 
The enzyme is an apparently symmetric dimer. Each subunit, of 
molecular weight 46,344 is a single chain of 412 amino acids. 
Attempts have been made to establish the significance of this 
dimeric aggregation. Upon succinylation of the amino groups 
with succinic anhydride (30, 31) and amidation of the carbox-
ylate groups with lysine methyl ester (32), lowered specific 
8 
activity was observed with the reversibly dissociated monomeric 
AAT. It is impossible to tell whether the decrease in specific 
activity is the result of monomerization in itself or of other 
chemical and conformational modifications. AAT can be dis­
sociated at high dilutions (2.5-250 yg/ml, pH 8, 20°C) (33, 34, 
35), with a moderate increase in specific activity. However, 
there is still controversy over the interpretation of the data 
concerning dimer-monomer equilibrium of AAT (36, 37, 38). 
Recently, Boettcher and Martinez-Carrion (39) prepared hybrid 
dimeric AAT containing one sodium borohydride-reduced monomer 
(pyridoxamine phosphate (PMP) form) and one native monomer and 
concluded that no interactions occur between active sites. No 
difference in the equilibrium constants or rates of reaction 
between the native and the hybrid enzymes was observed. The 
conclusion can not be overrated, since the recombination of 
native subunits could occur during the course of transamination. 
1. Spectral properties 
The chromophore PLP is sensitively dependent upon struc­
tural factors and environment and acts as a natural probe at 
the active sites of PLP-dependent enzymes. The protonated 
forms of AAT absorbing maximally at 23.2 kK (430 nm) (1 kK = 
10^ cm~^) have been shown to be internal Schiff bases with 
E-amino groups of lysine residues of the protein. This 
protonated internal Schiff base dissociates to give an 
9 
absorption band at about 27.6 kK (362 nm). The possible 
structures are shown below. 
protein protein 
H 
0 0 -H .+ © 
6.3 ^  
23.2 kK 27.6 kK 
In model systems, spectra of PLP-containing Schiff bases change 
little with changes in the state of dissociation of the ring 
nitrogen. The position of the absorption maximum is somewhat 
different from that of the corresponding model compounds (for 
example, the nonprotonated Schiffs base of L-leucine with 5-
deoxypyridoxal absorbs at 29.2 kK (40)), probably because of 
the particular environment provided by the protein. An 
alternative structure for the internal Schiff's base came from 
Turchin's NMR investigation (41) and the model study by 
Fisher and Metzler (42). Fisher's compound (shown as follow­
ing) absorbs at 27.5 kK, a position similar to that observed 
for the native enzyme. Therefore, an azomethine double bond 
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turned away from the phenolate was proposed for the structure 
for the internal Schiff base. A peculiarity is the exception­
ally low pK^ of the imino nitrogen in the enzyme (pK^ = 6.3, 
pK^ of model compounds = 11 ~ 12), which could be partly 
explained by a protonation of the ring nitrogen induced by a 
residue at the active site (43) ; an additional factor could be 
the existence of a hypothetical positively charged group of 
the protein in the proximity of the phenolate of the coenzyme 
(43) . 
2. Mechanism of transamination 
The general theory of PLP-catalyzed transamination was 
developed in 1953-54 by Braunstein and Shemyakin (44) and 
independently by Metzler et (45). A possible mechanism 
for AAT which is consistent with this theory is summarized in 
Figure 1. Amino acids react only with the active nonprotonated 
aldimine form of AAT (46) . As demonstrated by Cordes and Jencks 
(47) and Jencks and Cordes (48) in model experiments, an amino 
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acid (with nonprotonated amino group) will form a pyridoxylidene 
Schiff base much more rapidly by a reaction of carbonyl transfer 
from an imine of the coenzyme (transaldimination) than by con­
densation with the free aldehyde. Therefore, a tetrahedral in­
termediate (Figure 1, stage 2) was proposed for the transaldim­
ination. Intermediates which absorb at 23.2 kK and 20.4 kK 
(Figure 1, stages 3-5) were observed with the reactions of quasi-
substrates D,L-a-methylasparate and D,L-3-hydroxyasparate with 
AAT (49, 50,46). Saturation of AAT with asparate also produces 
peaks at 23.2 kK, 20.4 kK and 30.3 kK (51). The quinonoid in­
termediate (Figure 1, stage 4) absorbing at 490 nm was also seen 
in nonenzymatic systems (52r-53) . The successful isolation of a 
1,4-dihydropyridine formed in the reaction mixture of pyridoxal 
and diethylaminomalonate (54) further supports the postulated 
existence of a quinonoid intermediate. Hydrolysis of the 
ketimine (Figure 1, stage 5) and dissociation of the keto acid 
product from the enzyme terminates the half-reaction and 
leaves the enzyme in a PMP form. P. second substrate a-keto 
acid enters into the active site and reverses the course of the 
half-reaction, reconverting the enzyme to its PLP form. 
Model systems play a decisive role in exploring the 
mechanism of PLP-dependent reactions. However, model system 
studies could not portray the tremendous catalytic ability of 
the enzyme. Extensive kinetic studies on the enzyme (55-62) 
and on model systems (63-65) indicate that, even though the 
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protein 
-OOC 
CH-O P 
H 
ÔÛC I R 
H^ C 
0. 
I 
NH, 
O HgO P 
H 
27.6 kK 
(362 nm) 
"OOC f R 
X: 
H3C^ - N, 
23.2 kK 
(430 nm) 
stage 1 
CHgO P 
23.2 kK 
(430 nm) 
stage 3 
CH^O P 
Nc/ 
a 
H3C 
.CHgO P 
N. 
30.3 kK 
(333 nm) 
stage 5 
H 
30.3 kK 
(333 nm) 
stage 6 
CHgO P 
stage 2 
OOC R 
20.4 kK 
(490 nm) 
stage 4 
^^CH^O P 
O 
II 
C 
"OOC^ ^ R 
Figure 1. A possible mechanism for the "half-reaction" of 
enzymic transamination. Wave numbers designate 
absorption maxima. 
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general pattern is the same, the reaction rates are at least 
10^ times greater in the enzymatic than in the model system. 
Moreover, the enzyme displays a marked substrate specificity, 
which is lacking in the model system. Perhaps a dynamic 
molecular model can better invoke the roles of the catalytically 
active protein in contributing to the rate enhancement, in addi­
tion to its specificity. 
3. Dynamic aspects 
As suggested by Koshland's induced-fit theory (65) 
enzymatic active sites assume their functioning conformations 
when substrates are bound to the enzyme. In addition, the 
enzyme may undergo further conformational changes during the 
catalysis. Syncatalytic modification provides a clue to such 
a possibility. Riordan and Christen (66) had shown that, in 
the presence of the substrate pair, glutamate and a-ketogluta-
rate, one of totally five thiol groups of AAT became two orders 
of magnitude more reactive toward N-ethylmaleimide. Using ^Re­
labeled N-ethylmaleimide in similar experiments, Torchinsky 
et al. (67) identified this syncatalytically susceptible residue 
as a "semiburied" cysteine 390. Because of the nearly complete 
('^90%) inactivation of the enzyme and the decreased affinity 
for the substrates after the syncatalytic modification, it had 
been postulated that Cys 390 was catalytically essential. How­
ever, Birchmeier et a^. (68) studied syncatalytic modification 
of Cys 390 with a variety of reagents and reported that 60% 
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enzymatic activity was found with cyanide-modified enzyme. 
Therefore, suspicion was aroused against Cys 390 being essential 
to catalysis. 
Tyrosine 40 is another residue which can be modified 
syncatalytically. Turano et al. (69) first observed marked in­
activa tion of apoAAT on specific modification of one tyrosine 
(per monomer) with 1,5-difluoro-2,4-dinitrobenzene or tetrani-
tromethane. Cysteine residues were also oxidized by the latter 
reagent. 
Riordan and Christen (66) and Christen (70) found that 1.0-
1.4 tyrosine residues (per dimer) were syncatalytically modified, 
and the enzyme was inactivated 90-95%, Under the same experi­
mental conditions, tetranitromethane irreversibly oxidized cys 
390, which sufficed to cause ^>90% inactivation of the enzyme. 
In contrast to syncatalytic modification by tetranitromethane, 
the modification of Cys 390 alone did not lead to irreversible 
amination of the coenzyme (71, 72). However, independent 
modification of the functional Cys 390 followed by treatment 
with tetranitromethane in the absence of substrates results in 
the same chemical changes of AAT as observed on syncatalytic 
nitration. The results cast some doubt on essentiality of Tyr 
40 for catalysis. 
In addition to the spatial rearrangements of the func­
tional residues, changes in the environment of the active site 
and reorientation of the coenzyme may also occur. Several 
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lines of evidence support this idea. The first piece of 
evidence comes from the lack of circular dichroism (CD) in 
stage 3 (Figure 1) and a small negative CD in stage 4, but the 
rest of intermediates possess positive CD's. Further confirma­
tion comes from the studies by Arigoni (73) and Besmer and 
Arigoni (74) . Upon reduction of AAT with sodium borotritide he 
demonstrated that in the internal Schiff base, was added to 
the exposed re face of the imine bond, in contrast to the sub­
strate aldimine, in which the opposite, si face was shown to be 
exposed. Karpeisky and Ivanov (75) and Ivanov and Karpeisky (76) 
have suggested a dynamic molecular model in which the coenzyme 
ring is revolving 40® about an axis between 2-methyl and 5-chain 
during the transamination. This model is subject to improvement 
as new informations accumulate, since conformational changes in 
the protein will suffice to count for all the experimental data, 
too. As to the changes in CD, Ivanov and Karpeisky (76) attrib­
uted these to the formation and breaking of a hydrogen bonding 
between the pyridine N and an unidentified residue (HZ) of the 
enzyme. 
4. Stereochemical aspects 
Dunathan has pointed out ( 77, 78) a most important factor 
controlling the direction of PLP-dependent reactions, namely, 
which bond at C^^ is to be broken to form the guinonoid inter­
mediate. He postulated that the bond to be broken should lie 
in a plane perpendicular to that of the conjugated ir system. 
This conformation should minimize the transition state energy 
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by gain in resonance energy, therefore facilitating the bond 
breaking. Furthermore, in the case of AAT, the prototropic 
aldimine-ketimine rearrangement involves an acid-base catalysis. 
A cis proton transfer by a single acid-base group was also 
elucidated (79). 
5. Analogue studies 
Numerous PLP analogues modified in every position of the 
molecule have been synthesized (80, 12, 13), and used to 
elucidate the significance of structural features of the co­
enzyme. Based on analogue studies, it is almost certain that, 
essential roles in catalysis can be assigned to the 4-formyl, 
3-hydroxy and pyridine N. The 2-methyl group is not essential. 
The emphasis will be laid upon the 5-modified analogues. 
Wada and Snell (81) observed that the interconversion of 
PM and PL was catalyzed rapidly by apoAAT. The authors con­
cluded that the phosphate group played only a binding role and 
was not required for enzymic transamination. The ratio of 
concentrations required for half-saturation of the apoenzyme 
with PMP as the coenzyme (82) and with pyridoxamine as a co-
substrate for transamination with oxalacetate (81) is 
- = 4-4 X . .2000 
in(PM) ~2.3 X 10 
This ratio provides a rough quantitative estimate of the con­
tribution of the phosphate group to stabilization of the co-
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enzyme-apoenzyme linkage. When saturated with pyridoxamine, 
AA.T catalyzes the complete amino transfer reaction between 
aspartate and 2-oxoglutarate at 10 ^ times the turnover rate 
of intact holoenzyme. This suggests that the phosphate group 
is needed not only for firm binding but also for effective 
catalysis. Moreover, Hullar (83) was able to show that 5-
ethylenephosphonate analog (EPA) of PLP possessed only 2% 
activity of apoAAT-PLP. Furbish et a2. (84) studied 5-
modified analogues with apoAAT and found that they did not 
have coenzymatic activities with apoAAT. In contrast to the 
high spatial tolerance for 2- and 6-substituent in analogues, 
apoAAT can not tolerate analogues with even minor modification 
in the 5-position (see Table 1). It seems that a dianionic 
group in the 5-chain is important for catalysis. The impor­
tance of the bridge oxygen of PLP is also manifested in the 
low coenzymatic activity of EPA. 
Two analogues, PLS (85) and VGA (86) turn out to be 
interesting active site labelling reagents for AAT. It was 
suggested that an unknown group X in the enzyme reacted with 
a Schiff base of PLS and the active site lysine, forming 
a thiazolidine ring. Subsequently, the loss of the 4' proton 
initiated the elimination of the sulfate and a methyl group 
was generated in the 5-position. Therefore, two residues 
in the active site were cross-linked through the coenzyme 
analogue. Presumably, VGA reacted in the same fashion except 
that the 5-vinyl double bond was saturated during the process. 
Table 1. Coenzymatic activity of 5-modified analogues of PLP. 
Analogue 5-side chain coenzymatic activity reference 
5-deoxy-Pl 
-CH3 none binds weakly 84 
MPA 
-CHgPOg^ none binds rapidly 84 
PL-5'-Me-phosphonate 
-CHgOP(CHgjOg" none binds rapidly 84 
5'-Me-PLP 
-CHfCH^jOPOg" 3% 84 
CMDPL 
-CHgCHgCOO" none binds rapidly 84 
ayanoethyl-PLP 
-CHgOPOg(CHgCHgCN)" variable 84 
5'-homo-PLP 
-CHgCHgOPO]^ 1% 87 
EPA 
-CHgCHgPOg^ 7% 10% 83, 88 
VPA -CHMCHPO^"(trans) 2% 17 -21% 83, 88 
PLS 
-CHg-OSO]" none 85 
VGA 
-CH=CH-C02-(trans) none 86 
19 
However, the coenzymatic activities of analogues vary from 
enzyme to enzyme. For instance, PLS has been tested with other 
apoenzymes. It was found to have 10 and 23% coenzymatic 
activity in tryptophanase and arginine decarboxylase (89) , 
respectively. However, it failed to activate the apoenzymes 
of brain glutamic acid decarboxylase (90), phosphorylase (91), 
aspartate-B-decarboxylase (92) and D-serine dehydratase (89) . 
CMDPL was not found to have coenzymatic activity in 
tryptophanase (93), arginine decarboxylase (94), D-serine 
dehydratase (95) or AAT (84). However, one may consider its 
use as an antibacterial agent. It has been found that bac­
terial aposerine dehydratase binds CMDPL with a higher binding 
constant than is found with PLP itself. 
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III. EXPERIMENTAL 
A. Materials 
1. Analogues of pyridoxal 5'-phosphate 
Diethyl 5-(4-formyl-3-hydroxy-2-inethyl) pyridylmethyl 
phosphonate [(EtJgMP] was synthesized by Kevin Kelly, according 
to Dr. Chuzo Iwata's unpublished procedure of this laboratory. 
5-{4-Fonnyl-3-hydroxy-2-methyl) pyridylmethyl phosphonic 
acid (MPA) and its monoethyl ester derivative (EtMP) were 
obtained from acid hydrolysis of (Et)2MP, followed Dowex 50W-X4 
(ion exchange resin) column separation procedure developed by 
the author. 
Ethyl pyridoxal 5'-phosphate (EtPLP) and methyl pyridoxal 
5'-phosphate (MePLP) were made essentially according to the 
procedure of Murakami and Iwanami (96) and modified by the 
author. 
5-Deoxypyridoxal 5'-sulfonate was synthesized by . 
Bolden (97). 
5*-Carboxymethyl pyridoxal-5-deoxypyridoxal (CMDPL) was 
prepared by the author according to the procedure of Iwata and 
Metzler (98). 
5'-Carboxymethyl pyridoxamine-5-deoxypyridoxa1 dihydrochlo-
ride (CMDPM) was prepared by Iwata and Metzler (98), and re-
crystalized from methanal-ether before use. 
5-(4-Formyl-3-hydroxy-2-methyl) pyridyl ether phosphonic 
acid (EPA) was first synthesized by Hullar (83) and was 
21 
prepared here by Dr. Tetsu Miura. 
2. Other chemicals 
All other chemicals were obtained from commercial sources 
and were reagent grade. 
Triethanolamine hydrochloride was prepared by dissolving 
reagent grade triethanolamine in a minimal amount of water in 
the presence of an-excess of HCl. The hydrochloride salt was 
precipitated after the addition of ethanol, and was recrystal-
lized three times from water-ethanol and three times from water. 
Ethanolamine was distilled before use. 
3. The enzyme 
Asparate aminotransferase was prepared in this laboratory 
(see Methods), and only the a subform was used for studies. 
B. Methods 
1. Preparation of holo aspartate aminotransferase 
The procedure is based on the method of Jenkins e;t al. 
(22)/ as modified by Martinez-Carrion et al. (Method A)(27), 
and is adopted from Yang's Ph.D. dissertation (99). 
2. Enzyme concentration 
Determination of the enzyme concentration was based upon 
4 4 
molar absorptivities of 6.36 x 10 and 6.55 x 10 at 35.8 kK 
for the apoenzyme and holoenzyme, respectively (84), and a 
molecular weight of 4.63 x 10^ (19) per subunit. 
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3. Activity assay 
Routine assays were performed by the method of Jenkins 
et al. (22)/ except that triethanolamine hydrochloride was 
used for the buffer instead of Tris. Oxaloacetate produced 
was followed at 35.7 kK on the Gary 1501. The absorption 
coefficient of oxaloacetate as given by Velick and Vavra (100) 
3 —1 -1 (0.57 X 10 M cm ) was used to express specific activity as 
ymole/min/mg of enzyme. AAT prepared in this laboratory was 
found to have specific activity of 210-260 ymole/min/mg. 
4. AAT resolution 
The native enzyme was resolved according to the method of 
Scardi et (101) , with an adaptation by Furbish et a^. (84) . 
The apoAAT thus prepared had little detectable activity (0.2%-
0.4% of that of the reconstituted AAT) and was reactivated to 
85-99% of the activity of the native enzyme under the condition 
described below. 
5. Activity measurement of apoAAT-analogue complexes 
—4 —3 ApoAAT ('^'10 M) was incubated with PLP analogue (^^0 M) 
for 20 min, then diluted to a final concentration of 10 ^-10 
in the assay solution. The reaction was allowed to proceed for 
10 min. 
6. Spectrophotometric measurement 
Absorption spectra were obtained on a Gary Model 1501 
recording spectrophotometer equipped with a Gary-Datex digital 
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output system and an IBM card punch. Spectra were corrected 
for turbidity and baseline errors. 
A JASCO Model ORD/UV-5 equipped with a Scientific SS-20-2 
Modification was used for the Circular dichroism (CD) measure­
ment. Ellipticity recorded on charts was manually transcribed 
at 2 nm intervals onto IBM cards and was converted to Ae and was 
replotted vs. wave number by the computer. 
Nuclear magnetic resonance (NMR) spectra were obtained on 
a Varian A-60, Hitachi-Perkin Elmer R20B, or Varian HA-100. 
IVhen samples were dissolved in organic solvents, tetramethyl-
silane (TMS) was used for internal standard. Otherwise TMS in 
a capillary was used for external standard, in order to be able 
to recover the material afterwards. 
Mass spectra were obtained using an AEI MS-902 mass 
spectrometer. 
7. Buffer systems 
When enzyme experiments were performed at high pH, the 
buffer was made from 0.2 M triethanolamine hydrochloride adjusted 
to pH 8.3 with sodium hydroxide. However, 0.01 M triethanolamine 
hydrochloride was used in the pH titration experiments- When 
experiments were carried out at low pH, the buffer was made from 
0.2 M acetic acid adjusted to pH 5.4 with sodium hydroxide. 
Double distilled water was used to prepare buffer solutions. 
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IV. RESULTS 
A. Organic Synthesis of Pyridoxal 
5'-Phosphate Analogues 
1. Attempted synthesis of 5'-bromo-5-deoxypyridoxal from 5'-
bromo-S-deoxypyridoxamine dihydrobromide by nonenzymatic trans­
amination catalyzed by aluminum (III) ion. Isolation of 5'-0-
methylpyridoxal 
CHoNH, Br 
HO HO 
OHCCO. Na (?) + glycine 
• 
MeOH JJ A1 H H Br H Br 
5'-Bromo-5-deoxypyridoxamine dihydrobromide was 
synthesized according to the procedure of Khomutov (Bolden 
(97)). To a two liter solution of 0.0005 M (0.3 g) of methanolic 
5 '-bromo-5-deoxypyridoxamine dihydrobromide, (00025 M, 0.6 g) of 
sodium glyoxylate was added. The reaction mixture was stirred 
slowly for 5 min after which 0.00025 M (0.2 g) of aluminum ni­
trate nonahydrate was added. After stirring for 10 min, the 
mixture was allowed to stand for 2 hours until the peak ration 
^25 Skk'^^SS 8kk 0« 1 NaOH reached 3.5. After rotary evapora­
tion the residue was dissolved in a minimal amount of water and 
applied to a column (1.5 cm X 25 cm) of Amberlite CG 50 (100-200 
25 
mesh) ion-exchange resin in the acid form. The column was 
eluted with water at a rate of 60 ml/hr. The fractions with 
^25 8kk^^33 8kk greater than 5.3 were pooled with lyo-
philized. Yield: 8 mg. A reason for the low yield was that 
the product was volatile. Yellow materials were found in the 
condensing pot during the lyophilization. An attempt to sublime 
the reaction residue directly did not succeed because aluminum 
ion complexed with the product. 
A high resolution mass spectrum showed a parent ion peak 
at 181.07445, which gave a formula of (exact mass: 
181.07389) with an error of 3 ppm. The product refluxed in an 
alkaline solution for a few hours did not change to pyridoxal. 
So a structure of the product could be proposed as following: 
A possible reaction mechanism will be discussed later on. 
2. N-(2-Methyl-3-hydroxy-5-hydroxymethyl-4-pyridylmethylene)-
p-toluidine 
CHO 
p-tnlnid^ne 
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The commercial p-toluidine was recrystallized from water, 
and was thereafter sublimed. Pyridoxal hydrochloride was 
neutralized with sodium bicarbonate to give its free base. 
Pyridoxal (3 g, 0.018 mol) was added to 200 ml of ethanol. The 
solution was stirred at 40®C until most of pyridoxal was dis­
solved. g-Toluidine (2.1 g, 0.020 mol) was then added and 
was stirred for 10 min. A yellow precipitate formed imme­
diately. It was filtered and washed with three portions of 
ether and three portions of 100 ml each of water, giving 3.8 g 
of product. 
The filtrate was evaporated under vaccum, and washed with 
ether and water the same way but with 20 ml for each portion. 
0.25 g of product was recovered. Yield: 88%. The product 
can be recrystallized from ethanol or chloroform. Mass 
spectrum (m/e) : 256.3 (M"*") . NMR: In DMSO-dg, Ô 7.32 s, 
6 7.92 s, ô 9.12 s. Two methyl peaks were buried by a DMSO peak 
and the 5-methylene peak was broad. However they can be seen 
in CDClg solvent. 
In CDClg, 5 2.42 s, 2.58 s, 6 4.89 s. 
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3. N- (2-methyl-3-hydroxy-5-bromoinethyl-4-pyridylmethylene) -
p-toluidine hydrobromide 
The Schiff base of pyridoxal and p-toluidine (0.1 g) was 
added to 40 ml of anhydrous benzene. The solution was stirred 
and heated until the Schiff base was dissolved. 0.04 ml of 
S0Br2 was added. The precipitate was filtered and washed with 
anhydrous benzene three times. 0.12 g of product was obtained. 
Mass spectrum (m/e) : 320 (M + 2"*") and 318 (M^) with equal 
intensity (an indication of the existence of one bromine), 256 
(M^ of starting material). Judging from the peak ratio of 
(320 + 318)/256 in the mass spectrum, a 54% yield was obtained. 
When the product dissolved in the water, the bromo Schiff base 
was proven to cyclize to the following compound. Both the 320 
(M + 2^) and 318 (M^) peaks disappeared to give rise to a peak 
at 238 in the mass spectrum. 
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N-^OyCH, 
Ho 
H3C 
H Br H Br 
CH. 
Two spots could be separated from the reaction product on 
TLC (solvent: ethyl acetate), with R^'s 0.85 and 0.40. The 
spot of Rg 0.4 was demonstrated by its mass spectrum to be the 
starting material. The starting material was also obtained by 
a crystallization from acetone-skelly A. Attempts were made to 
purify the bromo Schiff base on a silica gel column (eluted 
with ethyl acetate). 
However, the bromo Schiff base appeared sensitive to 
moisture (and/or air). A black yellow material remained after 
concentration with a rotary evaporator. A major peak at 238 
in the mass spectrum was found for this black yellow residue, 
which suggested that the bromo Schiff base was cyclized. 
Likos (102) studied the reaction of glutamic acid decar­
boxylase with a substrate analogue serine-o-sulfate and pro­
posed structure A for its dephosphorylated product as following; 
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+ 
N-CH,CH_-OH 
CH 
0 
c 3 
Compound A 
Since glutamic acid decarboxylase can be utilized only once to 
produce stoichiometric amount of the product, it's difficult to 
prepare enough compound for characterization. It would be 
desirable to synthesize compound A so that we could compare its 
properties with those of the enzymic product side by side. 
4. Organic synthesis of the product of glutamic acid 
decarboxylase and serine-o-sulfate (compound A) 
HBr 
^^N-(CH2)2-0H 
HO HO 
product 
H H 
-4 To a one ml solution of 0.025 ml (4.1 X 10 mol) of 
ethanolic ethanolamine, 5 mg (1.3 X 10~^ mol) of the bromo 
Schiff base was added. The mixture was stirred for a few 
minutes. A bright yellow band was separated on TLC (Eastman 
Chromagram Sheet, 13181 silica gel, solvent :acetone) and was 
eluted by ethanol. After rotary evaporation a small amount 
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of water was added to dissolve the residue. The water was then 
evaporated under reduced pressure. 2.6 mg of product was 
obtained. Much of the product probably was trapped by the 
viscous ethanolamine which was present in excess on TLC. 
A high resolution mass spectrum showed a parent ion peak 
at 210.10089, which gave a formula of ^ 10^14^2*^3 (^xact mass: 
210.10044) with an error of 2.2 ppm. The possible structures 
are as following: 
•N-CH^CHoOH HO 
CH HO HO 
B CD 
The structure B is impossible, because a mixture of pyridoxal 
and ethanolamine does not give the same spectral change with 
pH as is observed for the product. 
Structures C and D are essentially the same when dis­
solved in aqueous solutions. Their spectral change with pH 
should be the same way as that of compound A. Structure C 
actually is the hydrate form of compound A. 
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5. 5'-Bromo-S-deoxypyridoxal 
The hydrobromic salt of the bromo Schiff base (10 mg) was 
added to 4 ml of ethanol. The solution was stirred and 0.15 ml 
of 48% hydrobromic acid was added. After 30 min, the reaction 
solution was evaporated under vacuum to almost dryness. The 
resulting solution was applied on an Amberlite CG 50 (100-200 
mesh) column (1.2 cm X 0.6 cm), and eluted with water. After 
rotary evaporation, 7 mg of residue was obtained. Mass 
spectrum (m/e): 231 (M + 2^) and 229 (M^) with equal intensity, 
150 (m"*" - Br) , 107 (p-toluidine) . 
6. Diethyl 5-(3-hydroxy-4-hydroxymethyl-2-methyl) pyridyl-
methyl phosphonate (Iwata's unpublished procedure) 
CH OEt CH OEt 
CH_-^=0 
2 I 
OEt—^ OEt 
H^C N H 
I II 
This compound can be made in either of two ways 
4 1) To a suspension of 18.4 g (81 mmol) of a ,3-0-isopro-
pylidene-a^-pyridoxylchloride (103) (prepared from the corre­
sponding hydrochloride by neutralization with saturated NaHCOg 
and extraction with methylene chloride) and 12.0 g (87 mmol) of 
diethylphosphite in 240 ml of anhydrous ether was added 2 g 
(87 mmol) of sodium metal (one piece: 1 cm X 0.5 cm X 0.3 cm). 
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After refluxing 50 hr the mixture was filtered and the filtrate 
was evaporated. 
2) a'^,3-0-isopropylidene-a^-pyridoxychloride (21.8 g, 
97 mmol) was combined with triethylphosphite (25 g, 150 mmol) 
and refluxed for one hour at 150°C. After cooling excess 
triethylphosphite is removed under vacuum. 
Either residue may be purified by vacuum distillation, but 
a good vacuum (<0.3 mm) is necessary to prevent excessive 
decomposition from high pot temperature (185-190° @ 0.3 mm). 
Method "1" gave 52% diethyl a^,3-0-isopropylidene-a^-pyridoxyl-
phosphonate (I) after distillation. The residue can also be 
purified to a lesser extent by chromatography on alumina with 
benzene or cyclohexane. Mass spectrum of I (m/e): 329 (M^), 
271 (M^-CHgCOCHg), 243 (m/e 271-CO), 215 (M/e) 2A3-C^li^) , 106 
[m/e 271-P(0)(0Et)2]• NMR of I in CCl^: 1.18t (6H), 61.47s 
(6H), 62.24d (3H), 62.81d (2H), 63.94 (4H) sextet, 64.82d (2H), 
67.77d (IH). Values are given for the center of each set. The 
5'-CH2 protons have a large splitting (22 H^). Smaller 
splittings (^3Hz) were observed for the 2-CH^,4'-CH2, and 
6-H signals. 
A solution of 1.6 g (4.9 mmol) I in 20 ml of 1 N HCl 
was heated on a steam bath for 15 min, the cooled solution was 
neutralized with NaHCO^ and extracted with CHCl^. The CHCl^ 
solution was dried (Na2S0^) and evaporated. Recrystallization 
from benzene gave 0.9 g (60%) of II, mp 128-129°. Mass 
spectrum of II (m/e) : 289 (M"*") , 271 (M"*" - HgO) , 243 (m/e 271-
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CO), 215 (m/e 243-C^H^), 106 [m/e 271-P(0) (OEt)^] . 
Anal. Calcd. for 49.82; H, 6.97; N, 4.84. 
Found: C, 49.85; H, 6.83; N, 4.84. 
7. Diethyl 5-(4-formyl-3-hydroxy-2-methyl) pyridylmethyl 
phosphonate [(Et)2MP] (Iwata's unpublished procedure) 
To 3.0 g (10.3 mmol) of II in CHCl^ (200 ml) was added 
10 g of activated Mn02 (104). The mixture was stirred in the 
dark at room temperature. When TLC (in acetone) indicated corn-
due washed with CHCl^ until washings were colorless. After 
rotary evaporation the residue can be purified by recrystalliza-
tion (CHgClg-Skelly A, 1:6) or chromatography on alumina (elution 
with chloroform). Yield 53%, mp 70-73°. Mass spectrum of 
[(Et)2MPj (m/e) : 287 (m"^) , 259 (m"^ - CO), 231 (m/e 259 - CO 
or C^H^), 203 (m^ 231 - CO or C^H^), 123 (m/e 231 - P (0)2 (OEt)), 
122 (m/e 231 - P(0)(OH)(OEt)). NMR in CCl^: resembles that of 
I. The 5'-CH2 peaks disappeared when dissolved in alkaline 
D2O. 
Anal. Calcd. for ^^2^18^05^- C, 50.17; H, 6.32; N, 4.88. 
Found: C, 50.07; H, 6.34; N, 4.92. 
II (Et) 2MP 
plete conversion (12 hrs) the mixture was filtered and the resi-
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UV data: See Tables 2 and 3/ and Figure 2. 
Oxime of (EtJgMP: To a solution of 0.4 g (1.4 inmol) of 
(Et) 2 in 50 ml of ethanol were added 0.35 g (5 ininol) of 
NHgOH'HCl and 0.41 g (5 mmol) of NaOAC. The mixture was 
refluxed for 3 hr and evaporated under reduced pressure. The 
residue was extracted with hot ethanol several times. After 
removing ethanol, the residue was recrystallized from ethanol, 
giving 0.25 g (59%) of oxime of VIII, mp 227-228°. 
Anal. Calcd. for C, 47.68; H, 6.34. Found: 
C, 47.48; H, 6.09. 
8. 5-(4-Fo3rmyl-3-hydroxy-2-methyl) pyridylmethyl phosphonic 
acid and monoethyl 5-(4-formyl-3-hydroxy-2-methyl) pyridyl-
methyl phosphonate (MPA and EtMP) 
CHO OEt 
1 
CH_-P=0 
^ 1 
OEt 
CHO OH 
CH,-P=0 
^ ! 
0 
OEt 
I 
CHg-P=0 
^ I 
0 
N 
(Et)2MP 
A solution of 1 g (3.45 mmol) of Et2MP in 50 ml of 20% HCl 
was refluxed. The progress of hydrolysis was monitored by re­
moving aliquots into 0.1 HCl. The uv-visible absorption spectrum 
^29 5kk^ was noted. The reaction was carried out until the 
ratio attained a minimal value of 1.8. Approximately 5 hours 
were required to attain this value. The solution was 
of the hydrolysate was recorded. The absorbance ratio (A^^ 
Table 2. Band parameters for resolved absorption spectra (105). The symbols H^P, 
H2P etc. refer to the state of protonation of a compound; (a( and (h) refer to 
aldehyde and covalent hydrate respectively. The position v . height e , width W 
and skewness p are those of the fitted lognormal curves. The molar area a° is the 
measured area (a) of a band divided by the mol fraction of a given form present. 
A number of values for molar areas were assumed by comparison with other compounds. 
These are designated by asterisks. 
Ionic ^^(kK) Eg (mol W(kK) P a ^ f 
Analogue form cm ^ X 10~^) (km^mol"^) (km-mol"^) 
I. (EtlgMP 
a (+) 29.44 2.37 4.46 1.21 113.2 362 .313 
h(+) 33.78 6.98 3.20 1.51 245.9 358* .687 
a ( + ) 39.43 1.11 3.58 1.18 42.6 
a (±) 25.42 4.33 4.00 1.36 187.7 399 .470 
a (0) 28.24 2.20 4.70 1.32 111.7 271* .412 
h(±) 30.99 1.13 3.46 1.32 42.3 360* .118 
a (±) 36. 88 0.92 5.34 1.32 53.1 
39.38 1.82 4.40 1.40 87.3 
40.58 3.11 4.34 1.29 145.5 
Table 2 . (Continued) 
Ionic v^(kK) e^(mol 
Analogue form cm ^ X 10 
II. MPA 
H3P 
H2P 
a(-) 25.46 7.79 
h(-) 33.67 0.49 
a(-) 38.57 3.32 
a(-) 42.16 8.66 
a(+) 29.12 3.69 
h(+) 33.77 5.51 
a(+) 38.80 1.46 
a(±) 25.52 2.23 
a(o) 27.92 3.30 
h(±) 31.00 1.76 
h(o) 34.46 0.53 
37.92 1.67 
(km«mol (km«mol~^) 
1.35 
1.36 
1.30 
1.25 
375.0 
21.8 
169.2 
402.9 
408 
267* 
.918 
. 0 8 2  
1.30 
1.62 
1.18 
184.4 
207.3 
70.1 
504 
327* 
.366 
.634 
1.36 
1.32 
1.32 
1.36 
1.32 
96.5 
162.7 
63.4 
19.6 
82.7 
455* 
316 
352* 
210* 
.212 
.515 
.180 
.093 
Table 2. (Continued) 
Ionic v^(kK) e^(mol ^ « 
Analogue form cm ^ X 10 
HP 
a(±) 25.30 1.42 
a(o) 27.65 3.52 
h(±) 31.13 2.55 
h(o) 34.58 0.63 
37.84 2.99 
P 
a(-) 25.63 6.10 
h(-) 32.95 1.86 
36.89 2.97 
41.70 2.10 
42.29 9.07 
III. EtMP 
HgP 
a(+) 29.16 3.28 
h(+) 33.79 5.33 
a(+) 38.10 1.41 
(km*mol ^) (km*mol~^) 
1.36 
1.32 
1.32 
1.36 
1.32 
61.5 
173.9 
89.7 
23.3 
150.7 
455* 
348 
352* 
210* 
.135 
.499 
.255 
.111 
1.34 
1.36 
1.34 
1.25 
1.20 
313.3 
73.2 
151.7 
97.7 
473.2 
428 
273* 
.732 
. 2 6 8  
U) 
1.27 
1.46 
1.18 
160.3 
188.1 
53.9 
377 
327* 
.425 
.575 
Table 2. (Continued) 
Ionic Vg(kK) e^(mol ^-
Analogue form cm ^ X 10 
HP 
a(±) 25.60 2.34 
a(o) 28.13 2.86 
h(±) 31.11 1.24 
h(o) 34.70 0.28 
38.56 2.73 
40.40 2.70 
a(-) 25.59 6.71 
h(-) 33.17 0.62 
a(-) 37.49 2.78 
a(-) 41.75 7.66 
IV. EtPLP 
H2P 
a(+) 29.86 1.49 
h(+) 33.97 7.08 
a(+) 40.05 0.71 
p a a° f 
(km-mol ^) (km.mol 
1.36 101.3 455* .223 
1.32 145.5 245 .595 
1.32 46.3 352* .132 
1.36 10.4 210* .050 
1.32 137.6 
1.40 129.1 
1.32 334.5 367 .912 
1.36 23.9 273* .088 
1.44 150.2 
1.25 356.7 
to 
00 
1.24 
1.53 
1.18 
75.1 
255.8 
27.3 
324 
333* 
.232 
.768 
Table 2. (Continued) 
Analogue 
Ionic 
form 
Vo(kK) -1 Eg(mol 
cm"^ X 10"3) 
W(kK) P a 
(kiTi'mol"^) 
a* 
(km*mol~^) 
f 
HP 
a(+) 25.60 5.02 4.00 1.36 217.9 346 .629 
a (o) 28.47 1.00 4.70 1.32 50.7 224* .226 
h(±) 30.96 1.35 3.46 1.32 50.5 348* .145 
a (±) 36.72 0.98 4.92 1.32 52.0 
h(±) 40.37 0.75 4.40 1.40 36.0 
P 
a (o) 40.43 2.71 4.34 1.29 126.7 
Jtr 
a(-) 25.67 6.90 4.44 1.34 331.4 377 .879 
h(-) 33.42 0.72 4.26 1.35 33.0 272* .121 
a(-) 38.85 3.32 4.73 1.30 169.5 
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Table 3. Apparent pK^ values 
Analogues pK^ Values 
(Et)2MP 3.03, 7.00 
MPA 4.07, 6.76, 9.20 
EtMP 3.91, 8.21 
EtPLP 3.56, 7.63 
Figure 2 . Ionic forms of (Et) 
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concentrated under reduced pressure. The concentrate was 
applied to an 1.2 X 50 cm column of Dowex 50W-X4 (100-200 mesh) 
in h"^ form previously equilibrated with water. The column was 
-1 
eluted with water under nitrogen at a flow rate of 36 ml hr 
The elution profile was recorded by a uv monitor at 35.7kk. 
EtMP appeared in the second peak and MPA appeared in the third 
peak of the elution profile. The effluent was concentrated in 
vacuo, and lyophilized. Yield: 51 mg or 40% for MPA, 26 mg 
or 20% for EtMP. Both can be recrystallized from water-acetone. 
NMR of MPA in D2O: 62.38s (3H), Ô3.29d (2H), 67.5s (IH, 
broad), 610.13 (IH, broad). NMR of EtMP in DgO: 61.09t (3H), 
Ô2.31d (3H), Ô3.22d (2H), 63.71 (2H) sixtet, 67.41s (IHO, 
broad), 610.10s (IH, broad). Electrophoreasis: MPA and EtMP 
migrated toward the anode in about the same distances at pH 
6.4, but a little less than that of pyridoxal 5'-phosphate. 
One trace impurity in each sample of MPA and EtMP moved ahead 
and was detectable by fluorescence. 
UV data; See Tables 2 and 3, and Figures 3 and 4. 
9. Monoethyl pyridoxal 5'-phosphate (EtPLP) 
Triethylamine (0.04 g) was added to 2 ml of an ethanolic 
suspension of 0.1 g pyridoxal 5 '-phosphate- The mixture was 
stirred with 0.08 g of dicyclohexylcarbodiimide for 5 hrs. The 
solution was then filtered. After evaporation to dryness on a 
rotary concentrator the residue was dissolved in 1 ml of water 
and washed with ether several times. The solution was con­
centrated and applied on a column (1 cm X 40 cm) of Dowex 
Figure 3-. Ionic forms of MPA 
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50W-X4 (100-200 mesh) ion exchange resin in the acid form. 
The column was eluted with oxygen-free water at a rate of 50 
ml/hr. 10 ml fractions were collected. An 0.1 ml aliquot of 
each fraction was added to 2 ml of 0.1 N NaOH and the spectrum 
was recorded (for elution profile, see Figure 5). The frac­
tions with absorbance ratios A25 8kK^'^32 6kK S^^ater than 10 
were pooled and lyophilized. Yield: 45 mg or 41%. The 
product was recrystallized from water-acetone. NMR in DgO: 
(S1.17t (3H) , 02.62s (3H), 63.93g (2H) , ÔS.lSd (2H) , 66.57s 
(IH) , 08.28s (IH). Values are given for the center of each 
set. 
Electrophoresis ; The sample moved as a single spot toward 
the anode at pH 6.4 with a mobility less than that of PLP. One 
trace impurity, moving ahead of EtPLP were detectable by 
fluorescence. 
UV data; See Tables 2 and 3, and Figure 6. 
10. Monomethyl pyridoxal 5'-phosphate (MePLP) 
The compound was first synthesized by Pfeuffer et al. 
(106) by a 6-7 step procedure. However, the author was able to 
obtain the compound in one step using the same procedure in (9) 
except that methanol was substituted for ethanol. Yield: 42%. 
The product was recrystallized from water-acetone. NMR in DgO: 
63.1s (3H), 64.03d (3H), 65.55d (2H), 56.95s (IH). The chem­
ical shifts are 0.5 ppm more downfield, because helmreich 
et al. used DSS as the internal standard. 
Figure 5. Elution profile for the purification of EtPLP 
-X-X- absorbance at 25.8kK 
-0-0- absorbance at 32.6kK 
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B. Interactions of the Analogues with 
Apoaspartate Aminotransferase 
1. Binding to the apoenzyme 
When apoAAT was mixed with individual analogues in a ratio 
of about 1 to 0.75 at pH 8.3/ the absorption band of the free 
analogue at about 25.6 kK was shifted to the 26.4-28.0 kK 
region. This fact suggested binding of the analogue to apoAAT 
(Figures 7-11). An exception was (Et)2MP whose absorption 
remained at 25.6 kK. A small amount of absorption in the 23-
24 kK region which decreased with time was observed with the 
analogues MPA, EtMP, MePLP and EtPLP. In contrast to this 
behavior, the 23 kK shoulder increased with time with PLSN. 
There is always a positive circular dichroism (CD) correspond­
ing to the major absorption band and sometimes a negative CD 
corresponding to the shoulder (Table 4). 
2. Activity measurement 
None of these analogues has coenzymatic activity at pH 8.3 
except for EPA which possesses 7-10% of activity of the 
native enzyme (83,88). Activity measurement was done also at 
pH 7.5 and 6.5 with MPA. The latter was not active at those 
pH's either. ApoAAT was incubated with EtPLP for four hours 
before assay, in order to test the idea that EtPLP might be 
hydrolyzed to PLP as was cyanoethyl-PLP (85). No increase in 
activity was observed. 
Figure 7. Reconstitution of apoAAT with EtMP, (apoAAT was 
snbstracted), apoAAT, 5.51 x 10 EtMP, 4.14 x 
lO'^M 
1) 2.5 min after mixing 
2) 40 min 
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Figure 8- Reconstitution of apoAAT (5.55 x 10 ^M) with 
PLSN (4.18 X 10"^M) at pH 8.3. (ApoAAT was 
subtracted) 
1) 2 min after mixing 
2) 25 min 
57 
19.00 23.00 27.00 ^ 
WfiVENUMBER (KK) 
31.00 35.00 
Figure 9 . Reconstitution of apoAAT with PL (apoAAT was 
subtracted) 
1) 6 min after PL (4.81 x 10 ^M) was added to 
apoAAT (5.44 x 10 ^M) 
2) 12 min 
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-5 Figure 10. Reconstitution of apoAAT (5.53 x 10 M) with 
EtPLP (3.44 X 10~^M) 
1) 2 min 45 sec after mixing 
2) 7 min 
3) 30 min 
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Figure 11 . Reconstitution of apoAAT (5.6 x 10 M) with 
MePLP (3.55 X 10~^M) at pH 8.3 (apoAAT was 
subtracted) 
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Table 4. Summary of data for binding to apoAAT at pH 8.3 
Ana­
logue 
Concentration 
of apoenzyme 
Concentration 
of analogues 
Binding to 
apoenzyme 
Absorption Circular 
bands dichroism 
A A/A X 103 
X lO^(M) X 10^(M) (time) A ^ X 
max max 
c 
PLP 5.55 6.0 < 2 min 363 nm 362 nm 2.0 
(Et) gMP 4.92 3.77 - 25.6kK 
(391 nm) 
-
MPA 5.50 3. 60 3-5 min 23.6kK(424nmX~420 nm) 
28kK (357nm) 356 nm 
1.00+0. .02d 
EtMP 5. 51 4.14 '\'40 min 'V'24kK (417nm) (^^20 nm) 
27.4kK(365nra)363 nm 
1.00+0 .04^ 
PLSN 5.55 4.18 '^'25 min 'v23kK (435nm) ('v420nm) 
26.4kK(379nm) 366nm 
0. 60 
CMDPL 5.11 3.80 2-3 min 27.4kK 363nm 
(365 nm) 
1.54+0 .01® 
PL 5.44 4.81 'V'15 min 26.6kK(376nm)372 nm 
32.0kK(313nm) 
1.34 
EtPLP 5.53 3.44 '\'30 min ~23.5kK(426nm)363 nm 1.82+0 .06* 
27.4kK(365nm) 
MePLP 5.60 3.55 ~15 min 27.5kK(364nm)363 nm 2.20 
EPA 5.30 4.10 <2 min 27.6kK(362nm)360 nm 1.92+0.05^ 
indicates a partially "buried peak" on a shoulder. 
^Positions of small negative CD, if any, are given in the parentheses. 
^Data were taken from Furbish et al. (84). 
^An average value of three experimental data. 
®An average value of two experimental data. 
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3. Reduction of apoenzyme-analoque complexes by sodium 
Reduction of E-MPA and E-EtPLP at pH 8.3 caused an 
immediate loss of the major absorption band (28 kK and 27.4 kK, 
respectively) and replacement with an absorption band at 30.8 
kK. Solid trichloroacetic acid (just enough to precipitate 
the protein) was added. After centrifugation the supernatant and 
the precipitate were separated. The precipitate was dissolved 
in 6 M guanidine hydrochloride in order to take the spectrum. 
The chromophore was found in the protein solution, implying 
that it was bound to the protein. The mixture of apoAAT plus 
(EtJgMP was treated with sodium borohydride in the same way. 
The chromophore was found in the supernatant and was not bound 
with the protein (Table 5). 
4. Attempted displacement of analogues by PLP 
Two control experiments were done to determine whether 
apoAAT can still bind PLP after sodium borohydride treatment; 
_5 (i) ApoAAT (5.61 x 10 M) was treated with sodium boro­
hydride. The subsequent addition of PLP (5.56 x 10 ^M) at 
pH 5.4 gave rise to a 23.6 kK peak (Table 6). 
(ii) Equal amounts of apoAAT (5.34 x 10 ^M) and PLSN 
(5.51 X 10 ^M) were mixed at pH 8.3. About 56% of the active 
sites were saturated, as judged by the fact that the positive 
CD at 366 nm reached 56% of its maximum. A positive CD at 
326 nm resulted from the addition of sodium borohydride to the 
Table 5. Summary of data for reduction of 
borohydride 
apoenzyme-analogue complexes by sodium 
Analogue 
Concentration 
of apoenzyme 
X 10^(M) 
Concentration 
of analogue 
X 10^(M) 
Chromophore 
found with 
(Et)2MP 4.92 3.77 supernatant 
MPA 5.60 3.60 apoAAT 
EtPLP 5.47 3.70 apoAAT 
Table 6. Summary of data for displacement of analogues by PLP 
+ NaBH^ + PLP 
nJ (d 
c m c c 0 i 0 QJ 0 g 
•H X •H 4J N s -P tn C g 4J c 
Q) nJ c ^ nJ O 0 E nJ o H Q) in M H in •H r< M in •H 
Q 
o O 4-1 m o 4J 4J o •P 
c Çh H C C  1—1 '0 X C H 0) X X Q) nj Q) tfl Ml C O g 0) M 03 O nJ 
a fH 
O X O X 0 m u e o X o R O g w C CO ^ r< C W r< r< < 
B 0 0 O 0 o 4 «4 u U O 
Blank^ 5.61 5.56 23.6 
(424 
kK 
nm) 
MPA 5.43 5. 30 30.8 
(325 
kK 
nm) 
5.46 25. 6 
(391 
kK 
nm) 
EtMP 5.16 11.9 ~325 nm 5.73 365 
414 
nm 
nm 
2.33 
-0.71 
PLSN 
PL 
5.28 
5.18 
5.11 
5.45 
20 
56.1 
326 nm 
330 nm 
5.28 
5.75 
4.14 
360 
360 
ill 
nm 
nm 
nm 
nm 
8.3 
2.5 
ve^y^small 
EtPLP 5. 57 5.59 30.8 
(325 
kK 
nm) 
5.45 25.7 
(389 
kK 
nm) 
^Concentrations were calculated after the mixing of three components (apoAAT, 
analogue and PLP). 
b. The experiment was done at pH 5.4 
69 
above solution. After the residual sodium borohydride was 
_5 
allowed to react for another two hours, PLP (5.28 x 10 M) was 
added. A positive CD at 360 nm, developed with Ae= 8.3 
(compared to Ae of the holoenzyme = 16, PLP occupied about 52% 
of the active sites). ApoAAT (5.26 x 10 ^M) was saturated with 
-4 PLSN (2.03 X 10 M). After sodium borohydride reduction, the 
_5 
addition of PLP (5.75 x 10 M) resulted in a positive CD at 
360 nm (AE= 2.5), and a negative CD at 415 nm (Ae = -2.6) 
(Table 6). The above two control experiments indicate that 
reduced apoAAT can still bind PLP, and the more PLSN the apoAAT 
binds, the less binding sites are left available for PLP. The 
reason for this is that PLSN actually binds at the active site 
and inhibits the binding of PLP. E-MPA was reduced by sodium 
borohydride at pH 8.3. After 3 hours of reaction, PLP was 
added to the solution. A peak appeared at 25.6 kK, indicating 
that the PLP remained free and unbound (Figure 12, Table 6). 
EtMP and PL were individually added, gradually to apoAAT 
at pH 8.3 until there was no more increase in the positive CD 
corresponding to the original major absorption band. Sodium 
borohydride was then added and, after three hours, PLP was used 
in the attempt to displace the analogue. However, the results 
suggested that EtMP and PL were bound at the active site (Table 
6) . If the analogue were not fixed in the active site by 
reduction, displacement of the analogue, for example, EtPLP, 
could be observed by direct circular dichroism at pH 5.4. 
Figure 12 • Attempted displacement of MPA by PLP after 
reduction 
1) ApoAAT, 5.59 x 10~^M, MPA, 5.46 x 10~^M 
pH 8.3 
2) Sodium borohydride was added, pH 8.5 
3) PLP (5.38 X 10-5m) was added 
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Neither bound EtPLP nor free PLP absorb at 23.2 kK, but bound 
PLP does at pH 5.4. PLP was added to E-EtPLP at pH 5.4. An 
increasing 23.2 kK CD in company with a decreasing 27.6 kK CD 
indicated that PLP displaced EtPLP (Figure 13/ Table 6). 
5. Low pH titration of apoenzyme-analogue complexes 
Portions (2-5 ul) of 2 M sodium acetate buffer (pH 5.4) 
were added to E-MPA, E-PLSN and E-ETPLP, individually. The pH 
was brought down from 8.3 to 6.0-5.5. No lower pH titration 
could be achieved, because the apoenzyme was denatured at 
acidic pH. The weak absorption band in the 23-24 kK range 
decreased with decreasing pH, while the major internal Schiff 
base band increased (for example, see Figure 14). No drastic 
absorption change was observed. Since there was no distinct 
p]^ found for E-EtPLP, glutarate was complexed with E-EtPLP 
in an attempt to raise the pK of E-Et PLP (Jenkins and D'Ari, 
(107)). Portions (5-10 yl) of 2 M sodium acetate (pH 5.4) were 
added to the above solution, but there was no drastic spectral 
change even when the pH was brought down to 4.7 (Table 7, and 
Figure 15). An interesting fact is, the absorption spectrum of 
E-MPA changed with pH the same way as other analogues initially, 
then the peak at 23.1 kK did increase with decreasing pH with a 
concomitant decrease of the peak at 28 kK (Figures 16a, 16b, 
and 17). Two pKa's 8.2 and 7.0 were estimated (ionic strength, 
0.02-0.04). The same phenomenon would be expected for EPA, 
whose 5'-side chain is dianionic at pH 8.3, similar to MP A. 
Figure 13.. Displacement of EtPLP by PLP at pH 5.4 
1) Apo, 5.57 X 10"^M, EtPLP, 5.59 x 10"^M 
2) 8 min after the addition of PLP (5.5 x 10 
Apo, 5.49 X lO'^M, EtPLP, 5.50 x 10~^M 
3) 46 min 
4) 11 hr 
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Figure 14 • Low pH titration of E-EtPLP 
1) Apo, 5.50 X 10~^M, EtPLP, 5.60 x 10"^M, 
pH 8.25 
2) pH 7.61 
3) pH 6.14 
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Table 7. Summary of data for 
analogue complexes 
low pH titration of apoenzyme-
Analogue 
Concentration^ 
of apoenzyme 
X 10^(M) 
Concentration^ 
of analogue 
X 10^ (M) 
Low pH limit 
MPA 5 . 1 0  3 . 3 0  6 . 0  
EtMP 5 . 2 0  3 . 8 0  6 . 0  
PLSN 5 . 2 0  3 .  6 6  6 . 2  
EtPLP 5 . 4 7  3 . 7 0  5 . 5  
5 . 4 7 b  5 . 5 8  4 . 7  
EPA 5 . 5 6  3 . 8 1  7 . 3  
^Concentrations were calculated before sodium acetate 
buffer was added. 
^Glutarate (0.015 M) was added before titration. 
However/ the apoenzyme seemed to denature more easily with EPA, 
and the pH could not be lowered to less than 7.3. The spectrum 
did not change with pH above pH 7.3 (Table ?). 
6. High pH titration of E-EtPLP 
ApoAAT (5.47 x 10 ^ M) was reconstituted with EtPLP (3.7 x 
10 ^M) at pH 8.3. Portions (2-5 ^ 1) of saturated NagCOg solu­
tion were added to the above solution. The 27.4 kK peak under­
went a bathochromic shift to 26.6 kK as the pH was brought up 
to 10. Apparently, the coenzyme was released from the apo­
enzyme when the solution became basic. 
Figure 15 • Low pH titration of E-EtPLP-glutarate 
1) ApoAAT, 5.47 x lO" M, EtPLP, 5.58 x 10~ M 
glutarate, 0.015M, pH 8.3 
2) pH 5.0 
3) pH 4.74 
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Figure 16a.. Low pH titration of E-MPA 
1) Apo, 5.10 X 10 
pH 8.40 
2) pH 7.90 
3) pH 7.55 
-5 M, MPA, 3 ,30 X 10~^M 
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Figure 16b. pH titration of apoAAT-MPA 
3) pH 7.55 
4) pH 7.10 
5) pH 6.10 
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Figure 17. Ionic forms of E-MPA 
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7. Addition of L-glutamate to apoenzyme-analogue complexes 
L-glutamate was added to individual E-MPA, E-EtMP, E-PLSN, 
E-PL, E-EtPLP and E-MePLP solutions at pH 8.3. The PLP form 
(^^7 kK) was transformed into the PMP form (^31 kK). With 
EtMP and PLSN, a 24 kK absorption band was also observed 
(Figures 18-23 and Table 8). Various turn-over rates were seen. 
The transamination followed biphasic pseudo first order kinetics 
with E-EtMP, E-PLSN, E-EtPLP and E-MePLP as shown in Figures 24-
27. The author tentatively interprets this as following; The 
first step is a fast reaction representing the real rate of 
transamination, the second step is a slow reaction in which an 
equilibrium is reached, following a slow release of the PMP form 
of the analogue from the apoenzyme. This point will be further 
explained in the discussion section. 
= e^[X] + Ey[Y] + C 
where and are molar absorptivities, and A^ is the 
absorbance at time t. The solvent or background contribution, 
if any, is represented by C. Values of initial and final 
readings (for the absorption band of the PLP analogue) are 
+ C 
= EytXIo + C,  Since [X!^ = 
Figure 18. Reaction of apoAAT-MPA with L-glutamate 
(apoAAT was subtracted) 
1) ApoATT, 5.51 X lO'^M, MPA, 3.62 x 10~^M 
2) 2 min after the addition of L-glutamate 
(17 mM) 
3) 6.5 min 
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Figure 19. Reaction of apoAAT-EtMP with L-glutamate (apoATT 
was subtracted) 
1) ApoAAT, 5.53 X 10"^M, EtMP, 4.14 x 10~^M 
2) 2 min after the addition of L-glutamate 
(17 mM) 
3) 24 min 20 sec 
4) 43.5 min 
5) 130 min 
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Figure 20. Reaction of E-PLSN with L-glutamate (apoAAT was 
subtracted) 
1) ApoAAT, 5.55 x 10 M, PLSN, 4.18 x 10~ M 
2) 2 min after the addition of L-glutamate 
(17 mM) 
3) 6 min 
4) 9.5 min 
to 
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Figure 21. Reaction of E-PL with L-glutamate (the apoAAT 
was subtracted ) 
1) ApoAAT, 5.04 x 10 ^M, PL, 6.64 x 10"^M 
2) 30 sec after the addition of L-glutamate 
(6 X 10"^M) 
3) 3 min 
4) 6 min 10 sec 
5) 9 min 45 sec 
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Figure 22. Reaction of apoAAT-EtPLP with L-glutamate 
1) ApoAAT, 5.53 X 10~^M, EtPLP, 3.44 x 10~^M 
2) 2.5 min after the addition of L-glutamate 
(0.091 M) 
3) 16 min 
4) 34.5 min 
5) 1 hr 
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Figure 23. Reaction of E-MePLP with L-glutamate 
1) ApoAAT, 5.6 X 10"^M, MePLP, 3.55 x 10~^M 
2) 2 min after the addition of L-glutamate 
(0.017 M) 
3) 11 min 
4) 29.5 min 
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Table 8 .  Reaction with L-glutamate at pH 8.3 
Analogue 
Concentration^ 
of apoenzyme 
X 10^(M) 
Concentration^ 
of analogue 
X 10^(M) 
Concentration^ 
of L-glutamate 
(M) 
b 
^max 
kobs°x lo"^ Ao-At+o 
At+o 
MPA 5.06 3.32 0.017 30.8 
(325 
kK 
nm) 
- -
EtMP 5.07 3.80 0.017 23.8 
(420 
31.4 
(318 
kK 
nm) 
kK 
nm) 
6.7 8-1 0.12 
PLSN 5.10 3.83 0.017 24.2 
(413 
31.8 
(314 
kK 
nm) 
kK 
nm) 
36.7 s-1 2.23 
CMDPL 2.43 
2.29^ 
2.21 
2.22 
0.012 
0.003 
31.3 
(319 
31.3 
(319 
kK 
nm) 
kK 
nm) 
- -
PL 4.90 64.6 0.006 _e -
] 
-
EtPLP 5.53 3.44 0.019 31.8 
(314 
kK 
nm) 
10 s" 0.20 
MePLP 5.12 3.25 0.017 31.8 
(314 
kK 
nm) 
25 s~ 1 0.37 
Concentrations were calculated after the addition of L-glutamate. 
^New absorption band(s) appeared after the addition of L-glutamate. 
. refers to the slow reaction, see the text. 
d The reaction was run in the presence of 0.03 M of phosphite. 
®The peak was too high to measure. 
Figure 24. Pseudo first order plot for the reaction of apoAAT-EtMP with L-glutamate 
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Figure 25. Pseudo first order plot for the reaction of E-PLSN with L-glutamate 
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Figure 26. Pseudo first order plot for the reaction of E-EtPLP with L-glutamate 
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Figure 27. Pseudo first order plot for the reaction of E-MePLP with L-glutamate 
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Substituting into the rate expression X = [Xj^ e we obtain 
+ e {[X]q(1 - e"^^) } + C 
or At - = (e^ - Gy)[X]^e -kt 
\ ^00 -kt 
Hence, a plot of 5,n 
A^ - A t CO 
A - A 
o 03 
vs. t will be linear with 
slope -k, permitting evaluation of the rate constant without 
values for [X]^, and e^. Values of kg^g for the slow 
reaction were determined and are shown in Table 8. When E-PL 
(4.40 X 10~^M + 9.43 x 10 ^M) and L-glutamate (0.019 M) were 
-4 
mixed at pH 8.3, 3.4 x 10 M of PL was consumed in 20 sec 
according to the decreasing absorbance at 25.6 kK, and the 
active sites of the apoenzyme were still saturated with 
pyridoxal (similar to Figure 21, except the concentration of 
PL is higher). Therefore a k^^^ for the decay of E-PL can be 
calculated as following, assuming that the binding of PL to 
apoAAT and the release of PM from apoAAT were not the rate 
limiting steps; 
PL + E E-PL obs ^ E-PM E + PM 
kobs [E-PL] = 3.4 X 10"'^M/20 S 
kobs (4.40 X 10~^M) = 3.4 X 10*^20 s 
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E-CMDPL was converted to E-CMDPM in 2 min, so fast that no 
spectrum could be recorded. In the presence of phosphite anion 
(0.03 M) , the binding of CMDPL to apoAAT was inhibited and slow. 
Immediately after the addition of L-glutamate, the peak at 
27.4 kK dropped rapidly, resulting in a broad band centered at 
25.6 kK. The transamination was also inhibited and lasted for 
30 min. Again, this is a biphasic reaction (Figure 28). How­
ever, the slow reaction followed a curve in the pseudo first 
order plot. The broad band appeared at 25.6 kK upon the addi­
tion of L-glutamate implied a mixture of free CMDPL and pro-
tonated external Schiff base. Therefore, the inhibition of 
binding of CMDPL to apoenzyme by phosphite may also contribute 
to the slow reaction as well as to the slow release of CMDPM. 
The slow reaction in Figures 24-27 was extrapolated to 
intercept the (A^ - A^) coordinate. The value of (A^ - A^) at 
t = 0 was obtained, representing the value at which an equi­
librium of [reacted E-PLP form]/[unreacted PLP form] was 
developed in the fast reaction. The reacted E-PLP form 
includes E-PMP form and other intermediates. Hence, the 
equilibrium ratio [reacted E-PLP form]/[unreacted PLP form] 
can be calculated from (A^ - A^^^)(Table 8). 
a-ketoglutarate (0.013 M) was added to the E-EtPMP solu­
tion at pH 8.3 after the transamination was complete, the peak 
at 31.8 kK decreased with time. The peak at 27.4 kK was buried 
under the absorption band of a-ketoglutarate, but an increasing 
Figure 28. Pseudo first order plot for the reaction of E-CMDPL with L-glutamate 
(in the presence of 0.03 M of phosphite) 
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shoulder still could be seen around 27.4 kK. A positive 
circular dichroism at 364 nm (27.5 kK) was recovered 57% of 
that of E-EtPLP. E-MePMP was converted back to E-MePLP by 
a-ketoglutarate (0.014 M) in a similar way, and 74% of the 
positive CD at 363 nm was recovered. A striking fact is that, 
except E-EPA, none of above E-PMP forms possess a positive CD 
as native E-PMP does. Excess CMDPM (0.11 M) was combined with 
apoAAT (2.80 x 10 ^M) at pH 8.3 and still no positive CD 
corresponding to 31.3 kK absorption can be seen. Although the 
concentration of CMDPM needed to combine apoAAT has not yet 
been established, it seems unlikely that 0.1 M of CMDPM is 
still not high enough to bind apoAAT. Another sample of 
E-MePLP was allowed to react with L-glutamate in order to take 
CD with time at 314 nm immediately after the mixing. There 
was no obvious increase in CD in the period of 13rd s - 2nd 
min. 
8. Addition of D,L-a-methylaspartate to apoenzyme-analpgue 
complexes 
D,L-a-methylaspartate was mixed with E-MPA, E-EtMP, E-PLSN, 
E-CMDPL, E-PL, E-EtPLP and E-EPA individually at pH 8.3 (Table 
9). There were no significant changes in the spectra observed 
with E-EtMP, PLSN and EtPLP. In the case of E-CMDPL, a small 
shoulder rose in 23-24 kK region (Figure 29) accompanying a very 
small negative CD at 415-425 nm. The absorption of E-PL under­
went a bathochromic shift (Figure 30) and a very small CD 
Figure 29. Reaction of E-CMDPL with D,L-a-inethyl-
aspartate at pH 8.3 (apoAAT was subtracted) 
1) ApoAAT, 5.11 X 10~^M, CMDPL, 3.8 x 10~^M 
2) D,L-a-methylaspartate (7.8 x 10~^M) was added 
apoAAT, 5.0 X 10~^M, CMDPL, 3.68 x 10~^M 
D,L-a-inethylaspartate (3.2 x 10~ M) was added 
apoAAT, 4.48 X 10~^M, CMDPL, 3.33 x 10"^M 
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Figure 30. Reaction of E-PL (5.44 x 10 M + 9.56 x 10~ M) 
with D,L-a-methylaspartate at pH 8.3 (apoAAT was 
subtracted) 
— 3 1) D,L-a-methylaspartate (7.7 x 10 M) was 
added, apoAAT, 5.28 x 10"^M, PL, 9.28 x 10~^M 
2) D,L-a-methyl aspartate (2.2 x 10 ^M) was added, 
apoAAT, 4.98 x 10~^M, PL, 8.75 x 10~^M 
3) D,L-a-methyl aspartate (7.8 x 10 ^M) was added, 
apoAAT, 3.8 x 10~^M, PL, 6.69 x 10"^M 
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developed at about 430 nm. However, E-MPA and E-EPA underwent 
a distinct transformation in the 23.0 kK absorption band (Table 
9 and Figures 31 and 32). The band increased in height and a 
negative CD was also induced. 
9. Addition of D,L-erythro-B-hydroxyaspartate to apoenzyme-
analogue complexes 
A 20.4 kK absorption band was observed with E-MPA, E-EtMP, 
E-PLSN, E-CMDPL and E-PL immediately after D,L-erythro-6-
hydroxyaspartate was added. E-EtPLP was the only exception 
(Table 10, Figures 33-37). The circular dichroism was examined 
with E-MPA, E-CMDPL, E-PL and E-EtPLP. A negative CD corre­
sponding to the 20.4 kK absorption band was seen with E-CMDPL. 
The absorption was too low (Figure 37) to relate any negative 
CD to the 20.4 kK absorption band with E-PL. In all three 
cases, in contrast to the native enzyme, there was still no 
positive CD corresponding to the E-PMP forms. 
10. Curve fitting 
Experimental absorption spectra can be fitted with log-
normal distribution curves (105) and can be resolved into indi­
vidual components. Individual spectra of E-MPA, E-EtMP, E-
CMDPL, E-EtPLP, E-MePLP and E-EPA were fitted in order to 
analyze band position (v^), peak height (e^), band width (W) 
and skewness (p.) (see Figure 38-43). 
Table 9. Summary of data for reaction with D,L-a-methylaspartate 
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n 0 
r4 
X 
1 
MPA 4.62 3.12 0.034 23.2 kK 
(431 nm) 
^420 nm -0.75 
EtMP 2.60 1.98 0.034 - - -
PLSN 5.33 4.12 0.012 - - -
CMDPL 4.48 3.33 0.032 ~23.5 kK 
( 426 nm) 
^420 nm -0.38 
PL 3.80 6. 69 0.078 Bathochromic 
shift 
^430 nm too small 
EtPLP 5.31 3.29 0.035 - - -
EPA 3.82 2.95 0.073 23.0 kK 
(435 nm) 
^420 nm -0.76 
^New absorption band appeared after the addition of D,L-a-methylaspartate. 
indicates a partially "buried" peak, or a shoulder. 
Figure 3 1 .  Reaction of apoAAT-MPA with D,L-a-methyl aspartate 
at pH 8.3 
1) ApoAAT, 5.31 X 10~^M, MPA, 3.58 x 10~^M 
2) D,L-a-methylaspartate (7.5 x 10 ^M), apoAAT, 
5.16 X 10~^M, MPA; 3.47 x 10"^M 
3) D,L-a-methylaspartate (3.4 x 10 ^M), apoAAT, 
4.62 X lO'^M, MPA, 3.12 x 10"^M 
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Figure 32. Reaction of apoAAT-EPA with D,L-a-methyl-
aspartate at pH 8.3 
1) ApoAAT, 5.30 X 10~^M, EPA, 4.09 x 10~^M 
2) D,L-a-methylaspartate (7.6 x 10 ^ M) was added, 
apo, 5.29 X 10"^M, EPA, 4.08 x 10~^M 
3) D,L-a-methylaspartate (7.3 x 10 ^M) was added, 
apo, 3.82 X 10"^M, EPA, 2.95 x 10"^M 
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Figure 33. Reaction of E-MPA with D,D-erythro-6-hydroxy-
aspartate at pH 8.3 (apoAAT was substracted) 
2 min after the addition of D,L-erythro-g-
hydroxyaspartate (0.004 M) apoAAT, 5.42 x 10 M, 
MPA, 5.02 X 10~ M 
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Table 10. Summary of data for reaction with D,L-erythro-3-hydroxyaspartate 
Concentration^ Concentration^ Concentration of^ ^ Half^ 
Analogue of apoenzyme of analogue D,L-erythro-3- X ^ ' time 
X 1o5(M) X 10®(M) hydroxyaspartabe (hour) 
MPA 5.42 5.02 0.004 ~20.4 kK{ 490 nm) 
23.2 kK(431 nm) 
30.4 kK(319 nm) 
10 
EtMP 3.05 3.54 0.005 20.4 kK(490 nm) 
~24.0 kK{417 nm) 
31.4 kK(318 nm) 
5 
PLSN 5.46 4.38 0.004 20.4 kK(490 nm) 
24.8 kK(403 nm) 
31.6 kK(316 nm) 
8 
CMDPL 5.38 3.72 0.004 20.4 kK(490 nm) 
31.2 kK(321 nm) 
4 
PL 5.28 9.28 0.009 20.4 kK(490 nm) 
31.6 kK(316 nm) 
2.5 
EtPLP 5.31 3.29 0. 004 31.8 kK(314 nm) -
^Concentrations were calculated after the addition of D,L-erythro-3-
hydroxyaspartate. 
indicates a partially "buried" peak, or a shoulder. 
New absorption band(s) appeared after the addition of D,L-B-hydroxyaspartate. 
^Half time of the absorption band at 20.4 kK, approximately. 
Figure 34. Reaction of E-PLSN with D,L-erytho-B-
hydroxyaspartate at pH 8.3 (apoAAT was substracted) 
1) ApoAAT, 5.55 X PLSN, 4.45 x 10"^M 
2) 2 min after the addition of D,L-erythro-g-
hydroxyaspartate (0.004 M) 
3) 57 min 
4) 2 hours 
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Figure 35. Reaction with E-EtMP with D,L-erytho-B-
hydroxyaspartate at pH 8.3 (apoAAT was subtracted) 
1) ApoAAT, 3.10 X 10~^M, EtMP, 3.64 x 10~^M 
2) 2.5 min after mixed with D,L-erytho-3-
hydroxyaspartate (0.005 mM). ApoAAT, 
3.05 X 10~^M, EtNP, 3.54 X 10~^M 
3) 2 hrs and 10 min 
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Figure 36. Reaction of E-CMDPL with D,L-erythro-6-
hydroxyaspartate at pH 8:3 (apoAAT was subtracted) 
1) ApoAAT, 5.47 X 10~^M, CMDPL, 3.78 x 10~^M 
2) 6 min after the addition of D,L-erythro-6-
hydroxyaspartate (0.004 M) apoAAT, 5.38 x 
10~^M, CMPDL, 3.72 X 10"^M 
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Figure 37. Reaction of E-PL with D,L-erythro-6-
hydroxyaspartate at pH 8.3 (apoAAT was subtracted) 
1) ApoAAT, 5.51 X PL, 9.56 x 10~^M 
2) 2.5 min after the addition of D,L-erythro-6-
hydroxyaspartate (0.009 M), apoAAT, 5.28 x 
10~^M, PL, 9.28 X 10"^M 
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Table 11. Band parameters for resolved absorption spectra of 
E-analogue complexes 
Vg(kK) EQ (mol W(kK) p a° 
Analogue cm~^ X 10~^) (km-mol"^) 
E-MPA 23.43 1.067 4.070 1.269 46.725 
27.98 6.128 4.781 1.671 328.301 
E-EtMP 24.20 1.391 3.749 1.275 56.157 
27.48 5.810 4.019 1.475 256.017 
E-CMDPL 27.25 8.628 3.940 1.614 378.388 
E-EtPLP 27.41 7.297 3.830 1.460 305.878 
E-MePLP 27.41 6.651 3.972 1.480 289.742 
E-EPA 27.63 7.441 4.293 1.508 351.413 
Figure 39. Resolved absorption spectra of E-MPA 
XXX observed spectrum 
resolved individual spectra and fitted sum 
of the individual lognormals 
MOL.  ABSORPTIVITY 
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Figure 40. Resolved absorption spectra of E-EtMP 
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Figure 41. Resolved absorption spectrum of E-CMPLP 
Only the major absorption band was fitted with a 
lognormal curve. 
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Figure 42. Resolved absorption spectrum of E-EtPLP 
Only the major absorption band was witted with a 
lognormal curve. 
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Figure 43. Resolved absorption spectrum of E-MePLP 
Only the major absorption band was fitted with a 
lognormal curve. 
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Figure 44. Resolved absorption spectrum of E-EPA 
Only the major absorption band was fitted with a 
lognormal curve. 
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V. DISCUSSION 
A. Organic Synthesis of Pyridoxyl 5'-Phosphate 
In general, vitamin Bg derivatives (especially those 
modified in the 5'-chain) may be prepared from readily avail­
able vitamin Bg compounds. Several key intermediates have 
been developed for synthetic schemes, for example, 2^,3-0-
isopropylidene-2^-pyridoxyl chloride hydrochloride, isopropyl-
ideneisopyridoxal and 5*-bromo-5-deoxypyridexamine. These 
compounds have found extensive application in the modification 
of the 5'-positions ( 108, 103, 98, 109, 97). 
2 ,3-isopropylidene-
2^-pyridoxyl chloride 
hydrochloride 
CHO 
isopropylideneiso-
pyridoxal 
CHgNHg 
CH.Br 
5'-bromo-5-deoxy-
pyridoxamine 
The 4-hydroxymethyl group can be re-generated by acid 
hydrolysis of the isopropylidene. A 4-formyl group can be 
obtained by oxidation of a 4-hydroxymethyl or a 4-aminomethyl 
group. Among various oxidants, Mn02 appears to be the most 
satisfactory. However, in some cases, the oxidation step is 
difficult and low yields were obtained. The idea of using 5'-
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bromo-5-deoxypyridoxamine as a synthetic intermediate was adopted 
from the well-known model reaction, in which the amino group was 
transferred from pyridoxamine to glyoxylate catalyzed by 
aluminum ion (III) (45). Pyridoxamine 5'-thiophosphate was 
formed from 5'-bromo-5-deoxypyridoxamine and trilithium thiophos­
phate. Efforts were made to oxidize this compound through non-
enzymatic transamination by Khomutov (110) and by the author 
independently. None of us has succeeded. An attempt to make 
5'-bromo-5-deoxypyridoxal via the same scheme led to the 
isolation of 5'-0-methylpyridoxal (see IV. Results (1)). A 
possible mechanism is shown below: 
.+ 
CH_NH_ 
sodium glyoxylate 
•2HBr 
H 
H-C-CO 
I 
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This turns out to be analogous to the reaction of pyridoxal-
5'-sulfate with apoAAT (85), in which the sulfate was eliminated 
and a methyl group was generated in the 5-position. 
In many cases, PLP analogues have been isolated as Schiff 
bases. Schiff bases had been utilized as intermediates for 
the synthesis of PLP analogues modified in the positions other 
than 5'-position. It appeared that a pyridoxal Schiff base with 
a reactive group in the 5'-position would serve as an ideal 
intermediate for modifying the 5'-position. Therefore, the 
bromo Schiff base was synthesized (IV. Results (3)). The 
bromide is so reactive that it can react with many other reagents 
under mild conditions. £-Toluidine can be hydrolyzed off by 
acid or base to give back the 4-formyl group. This avoids the 
problem of oxidation. 5'-Bromo-S-deoxypyridoxal was made from 
the bromo Schiff base, which can also be a synthetic inter­
mediate if mild conditions are employed. 
B. Interactions of Analogues with Apoaspartate Aminotransferase 
1. Binding characteristics 
Several lines of evidence support the view that the 
analogues under study, except for (Et)2MP, are bound to apoAAT 
at the active site, (I). The absorption band of the free 
analogue at about 25.6 kK was shifted to the 26.4 - 28.0 kK 
region upon mixing with apoAAT. There was always a positive 
CD corresponding to this major absorption band, a character­
istic of bound PLP. However, the position of the major 
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absorption band was always shifted to an energy (Table 3) 
lower than that of the CD maximum. The amount of the shift 
varies from 13 nm for E-PLSN to 1 nm for E-MPA. This suggests 
that small amounts of free analogues were still present. A 
small amount of absorption in the 23 - 24 kK region which 
decreased with time, may be attributed to a "non-specific 
binding" (Furbish et al. (84)). The 23 kK shoulder increased 
with time with PLSN and also with E-CMDPL when CMDPL was in 
excess. This observation suggests that PLSN was poorly bound 
to the active site and that some free PLSN was moving into the 
nonspecific binding site immediately after mixing (2). 
Experiments in which PLP was utilized in an attempt to displace 
apoAAT-analogue (IV. Results, (3) and (4)) indicate that the 
analogues occupied the PLP binding site. 
2. Activity 
Analogues seemed to bind apoAAT in a nearly normal way, 
but except for EPA they gave no measurable activity. Although 
cyanoethyl-PLP activated apoAAT in a prolonged incubation (84 ) , 
EtPLP did not activate apoAAT. Apparently, the former 
analogue may be hydrolyzed in its specific way to PLP: 
0 H 
CHO ^ M 1 CHO 0 
CHg-0-P-0-CH?-C-CN I II 
2 I 2^, X;H,-O-P-O-
2 1 X;-^H 
+ CH2=CH-CN 
HX. 
^E 
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The presence of a dissociable a-proton adjacent to CN makes 
cyanoethyl-PLP a special case compared to EtPLP. 
3. Low pH titration 
A remarkable feature of the bound analogues (monoanionic), 
except MPA is that they do not undergo a spectral shift to 
23,2 kK at low pH as does native enzyme. The same phenomenon 
was reported by Furbish et a^. (84) with other analogues. 
They attributed this phenomenon as a result of a shift in the 
pK^ of the protonated imine to below 6.3. Charge effects on 
this pK^ have been reported elsewhere by Jenkins and L. D'Ari 
(107) , Marino et (111) , Fasella (112) , and Furbish 
et al. (84) . For example, glutarate was abè to raise the pK^ of 
E-CMDPL to 4.7. Therefore, it is reasonable to assume charge 
effects of these analogues on the pK^. In fact, the dianionic 
phosphonate group of MPA is in a close proximity to the imine 
nitrogen. The spectral change above pH of apo-MPA may be 
refered to the nonspecific binding characteristic, whereas 
the pK^ of approximately 7.0 is attributed to the protonated 
imine nitrogen. 
4. Transamination 
Although none of the analogues (except EPA) displays any 
activity in the assay, the apoAAT-analogue complexes do turn 
over with L-glutamate. That is, they undergo a half-trans-
amination reaction. 
The reactions of MPA and CMDPL were too fast to follow 
spectrophotometrically. However, for the other analogues 
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the reaction was clearly biphasic. Part of the reaction 
occurred very rapidly and part more slowly. The most striking 
feature is that, during and after the transamination, none of 
the amine (PMP) form possesses a positive CD. The circular 
dichroism is an indicator of an asyitimetic environment sur­
rounding the chromophase. The lack of a positive CD is indica­
tive of a different environment from that of the native enzyme. 
A difference in the orientation of the PMP form of the analogue 
and/or in the conformation of the protein could account for 
the CD result. Moreover, PL and PM were found (IV. Results, 
7) (81) to come off and on to the apoAAT rapidly during the 
reaction with amino acid or a-ketoacid. Therefore, a defect in 
binding ability of the analogue and a consequent inappropriate 
orientation of the analogue in the active site may well lead 
to the complete release of its PMP form from the active site. 
The biphasic kinetics may be interpreted as follows. The first 
step is a fast reaction representing the real rate of trans­
amination, the second step is a slow reaction in which an 
equilibrium is reached, following a slow release of the PMP 
form of the analogue from the apoenzyme. 
Fasella and Turano (32) have estimated that the binding free 
energy (-AG°) of the 5'-phosphate group is 6 0% (7 - 8 kcal/mole) 
of that (11 - 14 kcal/mole) of PLP molecule and 75% of that (9 -
11 kcal/mole) of PMP molecule. Consequently, a defective 
binding group in the 5'-position of the analogue should contrib-
i.ute to abortive binding and the release of the PMP form. 
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Furthermore, apoAAT-CMDPL is seven times more active in the 
presence of a high concentration of CMDPL than in its absence 
(84), inferring that the inactivity by CMDPL is partly a result 
of the weak binding of the PMP forms. Anions have been 
reported to be effectors for transamination (13). From IV. 
Results, 7 and Figure 28, the inhibition of binding of CMDPL to 
apoenzyme by phosphite may also contribute to the slow reaction 
as well as to the slow release of CMDPM. This fact is another 
indirect evidence that the PMP form comes off during the reac­
tion. Compatible with this is another observation that phos­
phate inhibits the transamination between PM and ketoacids 
catalyzed by apoAAT (82). 
Particularly intriguing is the fact that the magnitudes 
of the values for k^^^ are parallel to those of (Ag-A^^^)/ 
in the cases of E-EtMP, E-ELSN, E-EtPLP and E-MePLP. The 
explanation follows below. For the half transanimation reac­
tion: 
E + PLP —E-PLP E-PMP ^  E + PMP 
PLP and PMP represent the aldehyde form and the amine form of 
the analogue, respectively. For simplicity, intermediates 
between E-PLP and E-PMP, and the substrate L-glutamate are 
omitted in the scheme. The value of (A_-A.^_)/A.^_ reflects 
o t^o t->-o 
the equilibrium ratio between E-PMP (including intermediates) 
and E-PLP developed in the fast reaction. The fact that the 
fast reaction can't proceed all the way through and finally 
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the reaction rate is limited by a slow release of the PMP 
form, indicates that there are factor(s) which control the 
thermodynamic stability between E-PMP and E-PLP. These 
factor(s) are unfavorable to the formation of E-PMP form 
for E-EtMP, E-EtPLP and E-MePLP (see values 
in Table 8) . It is assumed that the values for k of the ana­
logues are identical since none of their PMP forms can bind 
properly in the active site on the basis of lacking in CD, 
Therefore, in the equilibrial state, a higher value of 
(A^-A^^Q)will be associated with a faster drop in the 
concentration of E-PLP, resulting in a higher value of k^^^ 
for the slow reaction. 
It is of interest to note that the size of the 5-chain 
plays a certain role in the slow reaction. Of the same length 
of the chain, MePLP is faster than EtPLP, and PLSN is faster 
than EtMP. 
An alternative explanation for the biphasic kinetics is 
the theory of half of the sites reactivity. Since apoAAT was 
only 65-75% saturated with analogues, it is possible that two 
different conformers exist, one is a dimer combined with two 
molecules of the analogue, another one is a dimer combined with 
one molecule of the analogue. These two different conformers 
displayed different reactivities. 
It is true that the overall reaction rates of E-EtMP, E-
PLSN, E-EtPLP and E-MePLP are slower than that of E-PL. How­
ever, whether the 5'-phosphate group has a role in catalysis 
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is not yet settled on the ground, unless the true transamina­
tion rate (fast reaction rate) is Measured. 
Wada and Snell (81) estimated that the turnover number of 
_ 3  
apoAAT saturated with pyridoxamine was 25, 10 that of native 
holoenzyme. It is possible that its true turnover number is 
higher than what they estimated, because PL which was formed 
during the course of the reaction, might possibly come off the 
active site (actually PL was loosely bound to apoAAT), affecting 
the overall rate of transamination. It would be expected that 
the turnover number for the half transamination should not be 
smaller than that for the overall transamination. By contrast, 
they obtained a turnover number of 10 for the transamination 
between PM (utilized as a substrate) and a-ketoglutarate 
catalyzed by apoAAT. It appeared that the rate limiting step 
for the transamination between PM and a-ketoacid must be 
either the release of PL from apoAAT or the binding of PM to 
apoAAT. A turnover number of 24 (0.4 s ^) for the transamina­
tion between PL and L-glutamate was obtained by the author. 
Compared to the result of Wada and Snell (81), this indicates a 
fact that the release of PM from apoAAT is faster than the 
release of PL from apoAAT. 
Another interesting fact is, that D,L-a-methylaspartate 
caused no significant changes in the spectra observed with 
E-EtMP, E-PLSN and E-EtPLP, which are monoanionic analogue 
complexes. This is parallel to the fact that their pK^'s are low 
and their Schiff base forms are hardly protonated. The only 
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exception among the monoanionic analogue complexes is E-
CMDPL, which had a small shoulder in the 23 - 2 4 kK region. 
E-PL underwent a bathochromic shift when reacted with D,L-a-
methylaspartate. Possibly it is due to the formation of Schiff 
base of free PL and substrate. However, a very small negative 
CD was observed with E-PL in the 23 - 24 kK region. E-MPA 
and E-EPA gave rise to a 23.2 kK peak, similar to that of the 
native enzyme, when D,L-a-methylaspartate was added. However, 
all the 23.2 kK absorption bands induced negative CD's while 
the CD of native enzyme is zero. 
E-EtPLP possesses the unique characteristic of not having 
a 20.4 kK intermediate with D,L-erythro-3-hydroxyaspartate. 
However, other analogues showed a 20.4 kK absorption band of a 
small to medium size similar to that of the native enzyme. 
E-MePLP was not tested with D,L-erythro-B-hydroxyaspartate. 
The bridge oxygen of the phosphate ester of PLP seems 
important for catalysis since E-EPA has only 7% - 10% activity 
of apo-PLP (83/88)• The phosphate ester may interact with the 
protein residue(s). Because: (1) It has been known that the 
5'-phosphate group can be split off by sodium borohydride only 
when PLP is bound to the enzyme (113). (2) Khurs and Khomutov 
(114) reported a partial splitting of the S-P bond when E-
pyridoxamine-5'-thiophosphate reacted with a-ketoglutarate or 
a substrate pair. The charge effects of 5'-chain on the 
activity are even more pronounced. None of two ester analogues 
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of PLP (Et-PLP and MePLP) displayed detectable coenzymatic 
activity. The length of the 5'-chain seems also critical for 
activity when compare MPA and EPA. 
In conclusion, the charges on the 5'-chain of analogues 
seem to affect the physical chemical properties of the active 
site and the equilibrium among the bound reaction inter­
mediates. The half-transamination reactions of E-EtMP, E-PLSN, 
E-EtPLP and E-MePLP follow biphasic kinetics, which may be a 
result of a slow release of the PMP forms of the analogues. 
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VI. SUMMARY 
A possible new intermediate for preparation of 5'-modified 
pyridoxai 5'-phosphate analogues, N-(2-methyl-3-hydroxy-5-
bromomethyl-4-pyridylmethylene) g-toluidine hydrobromide, was 
synthesized. Other 5'-modified analogues, diethyl 5-(4-
formyl-3-hydroxy-2-methyl) pyridylmethyl phosphonate, 5-(4-
formyl-3-hydroxy-2-methyl) pyridylmethyl phosphonic acid, 
monoethyl 5-(4-formyl-3-hydroxy-2-methyl) pyridylmethyl phos­
phonate, 5-deoxypyridoxal 5'-sulfonate, 5'-carboxymethyl-5-
deoxypyridoxal, monoethyl pyridoxai 5*-phosphate, monomethyl 
pyridoxai 5 '-phosphate, and 5- (4-formyl-'? -hydroxy-2-methyl) 
pyridylethyl phosphonic acid were also made in our laboratory 
in order to test with apoaspartate aminotransferase from pig 
heart muscle. 
With the exception of diethyl 5-(4-formyl-3-hydroxy-2-
methyl) pyridylmethyl phosphonate, all the analogues bond to 
apoaspartate aminotransferase. None of them, except the 
dianionic side-chain analogue, 5-(4-formyl-3-hydroxy-2-methyl) 
pyridylethyl phosphonic acid displayed detectable coenzymatic 
activity. There was no positive circular dichroism correspond­
ing to the amine forms of those analogues that had no coenzymatic 
activity. Apoenzyme-5-(4-formyl-3-hydroxy-2-methyl)pyridylmethyl 
phosphonic acid has a pK^ value around 7, other apoenzyme com­
plexes with the monoanionic side-chain analogues apparently 
have pK^ values below the 6.3 of the native holoenzyme. 
159 
The charges on the 5'-chain of the analogues seem to 
affect the physical chemical properties of the active site 
and the equilibrium among the bound reaction intermediates. 
The half-transamination reaction of the apoenzyme complexes 
with monoethyl 5-(4-formyl-3-hydroxy-2-methyl) pyridylmethyl 
phosphonate, 5-deoxypyridoxal-5'-sulfonate, monoethyl 
pyridoxal 5'-phosphonate and monomethyl pyridoxal 5'-phosphate 
follow biphasic kinetics, which may be a result of a slow 
release of the amine forms of the analogues. 
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